MedTrace Logo

A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

NCT00525408 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2012-03-12

No results posted yet for this study

Summary

This study proposed the comparison the overall survival, hematological toxicity, pain reduction score,PSA levels, tumor response, quality of life in two arms of HRPC patients from different parts of India.

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

BIOLOGICAL

Mycobacterium w.

Immunomodulator

DRUG

Docetaxel

Chemotherapeutic agent

Sponsors & Collaborators

  • Cadila Pharnmaceuticals

    lead INDUSTRY

Principal Investigators

  • Sudhir Rawal, MD · Rajiv Gandhi Cancer Institute

  • Arup Kumar Mandal, MD · Post Graduate Institute of Medical Education and Research, Chandigarh

  • Devakar Dalela, MD · Chatrapati Sahuji Mahraj Medical University

  • N K Mohanty, M.D. · Safdarjang Hospital

  • Jayesh Dhabalia, MD · SEth G S Medical College & KEM Hospital

  • Arun Chawla, MD · Kasturba Medical College

  • Sujata Patwardhan, MD · LTMMC & LTMGH

  • P G Jayaprakash, MD · RCC, Trivandrum

  • Amil Lal Bhat, MD · S.P. Medical College & A.G. Hospitals

  • Raju T Chacko, MD · Christian Medical College, Vellore, India

  • Sushil Bhatia, MD · Choithram Hospital & Research Centre

  • Kim Mammen, MD · Christian Medical College, Ludhiana

  • K C Lakshmaiah, MD · Kidwai Memorial Istitute of Oncology

  • Rajeev Gupta, MD · Patel Hospital Pvt. Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00525408 on ClinicalTrials.gov